Literature DB >> 22350023

Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy.

Hiroshi Okumura1, Yasuto Uchikado, Masataka Matsumoto, Tetsuhiro Owaki, Yoshiaki Kita, Itaru Omoto, Ken Sasaki, Toshihide Sakurai, Tetsuro Setoyama, Bunpei Nabeki, Daisuke Matsushita, Sumiya Ishigami, Yoshiyuki Hiraki, Masayuki Nakajo, Shoji Natsugoe.   

Abstract

BACKGROUND: Definitive evaluation of surgical specimens obtained after neoadjuvant chemoradiation therapy (CRT) is important for assessing additional treatment or prognosis in patients with esophageal squamous cell carcinoma (ESCC). In this study, we examined the histological prognostic factors for ESCC patients treated with CRT and determined an appropriate strategy for their evaluation. PATIENTS AND METHODS: The present study involved 38 consecutive ESCC patients who underwent CRT followed by curative operation. CRT consisted of 5-fluorouracil plus cisplatin and 40 Gy of radiation. We examined histological variables as follows: CRT effect on primary tumor (T-effect: T-effective/T-ineffective), tumor depth (pT), lymph node metastases (pN: pN0/N1), number of lymph node metastases (number-pN), lymphatic invasion, and venous invasion. Univariate and multivariate analyses were performed to examine the independent prognostic factors. Survivals and mode of recurrence were then evaluated according to the independent prognostic factors.
RESULTS: In the univariate analyses, T-effect, pN, number-pN, lymphatic invasion, and venous invasion were found to be prognostic factors with p < 0.01, and pT was a factor with p < 0.05. In the multivariate analysis, pN and T-effect were independent prognostic factors. The five-year survival rate of pN0 patients was more than 75%, even though the T-effect was poor. The 5-year survival rate of patients judged as pN1/T-effective was 50%, whereas all of the pN1/T-ineffective patients died within 2 years with relapse disease.
CONCLUSION: The evaluation method using both pN status and T-effect is useful for assessing prognosis of ESCC patients treated with neoadjuvant CRT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350023     DOI: 10.1007/s10147-012-0383-y

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  14 in total

1.  The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer.

Authors:  Simon Law; Dora L W Kwong; Kam-Ho Wong; Ka-Fai Kwok; John Wong
Journal:  J Gastrointest Surg       Date:  2006-11       Impact factor: 3.452

2.  Endoscopic ultrasonography is useful for monitoring the tumor response of neoadjuvant chemoradiation therapy in esophageal squamous cell carcinoma.

Authors:  Tetsuhiro Owaki; Masataka Matsumoto; Hiroshi Okumura; Yasuto Uchicado; Yoshiaki Kita; Tetsuro Setoyama; Ken Sasaki; Toshihide Sakurai; Itaru Omoto; Mario Shimada; Fuminori Sakamoto; Heiji Yoshinaka; Sumiya Ishigami; Shinichi Ueno; Shoji Natsugoe
Journal:  Am J Surg       Date:  2011-06-16       Impact factor: 2.565

3.  Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution.

Authors:  S Natsugoe; H Okumura; M Matsumoto; Y Uchikado; T Setoyama; N Yokomakura; S Ishigami; T Owaki; T Aikou
Journal:  Dis Esophagus       Date:  2006       Impact factor: 3.429

4.  Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Authors:  Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

5.  Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT).

Authors:  Stephen G Swisher; Wayne Hofstetter; Tsung T Wu; Arlene M Correa; Jaffer A Ajani; Ritsuko R Komaki; Lucian Chirieac; Kelly K Hunt; Zhongxing Liao; Alexandria Phan; David C Rice; Ara A Vaporciyan; Garrett L Walsh; Jack A Roth
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

6.  Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma.

Authors:  Hiroyuki Takatori; Shoji Natsugoe; Hiroshi Okumura; Masataka Matsumoto; Sumiya Ishigami; Tetsuhiro Owaki; Takashi Aikou
Journal:  Oncol Rep       Date:  2005-04       Impact factor: 3.906

7.  Recurrence after neoadjuvant chemoradiation and surgery for esophageal cancer: does the pattern of recurrence differ for patients with complete response and those with partial or no response?

Authors:  Robert A Meguid; Craig M Hooker; Joshua T Taylor; Laurence R Kleinberg; Stephen M Cattaneo; Marc S Sussman; Stephen C Yang; Richard F Heitmiller; Arlene A Forastiere; Malcolm V Brock
Journal:  J Thorac Cardiovasc Surg       Date:  2009-12       Impact factor: 5.209

8.  Radiotherapy alone and chemoradiation for nonmetastatic esophageal carcinoma. A critical review of chemoradiation.

Authors:  M J John; M S Flam; P A Mowry; W J Podolsky; A M Xavier; P S Wittlinger; A Padmanabhan
Journal:  Cancer       Date:  1989-06-15       Impact factor: 6.860

9.  The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma.

Authors:  H Okumura; S Natsugoe; M Matsumoto; Y Mataki; H Takatori; S Ishigami; S Takao; T Aikou
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

10.  Expression of osteopontin in oesophageal squamous cell carcinoma.

Authors:  Y Kita; S Natsugoe; H Okumura; M Matsumoto; Y Uchikado; T Setoyama; T Owaki; S Ishigami; T Aikou
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

View more
  12 in total

1.  Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.

Authors:  Junya Oguma; Soji Ozawa; Kazuo Koyanagi; Akihito Kazuno; Miho Yamamoto; Yamato Ninomiya; Kentaro Yatabe
Journal:  Esophagus       Date:  2019-06-12       Impact factor: 4.230

2.  Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma.

Authors:  Chen Wu; Dong Li; Weihua Jia; Zhibin Hu; Yifeng Zhou; Dianke Yu; Tong Tong; Mingrong Wang; Dongmei Lin; Yan Qiao; Yuling Zhou; Jiang Chang; Kan Zhai; Menghan Wang; Lixuan Wei; Wen Tan; Hongbing Shen; Yixin Zeng; Dongxin Lin
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

3.  Prognostic factors associated with 18FDG-PET/CT in esophageal squamous cell carcinoma after trimodality treatment.

Authors:  Hsu-Kai Huang; Tsai-Wang Huang; Wei-Hsiang Feng; Ying-Yi Chen; Yen-Shou Kuo; Kuan-Hsun Lin; Yuan-Ming Tsai; Ti-Hui Wu
Journal:  BMC Cancer       Date:  2022-07-14       Impact factor: 4.638

4.  Factors Predicting Effectiveness of Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.

Authors:  Yu Ohkura; Masaki Ueno; Toshiro Iizuka; Shusuke Haruta; Tsuyoshi Tanaka; Harushi Udagawa
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

5.  Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery.

Authors:  Xingxing Wang; Hao Wang; Haixing Wang; Jie Huang; Xin Wang; Zhengzeng Jiang; Lijie Tan; Dongxian Jiang; Yingyong Hou
Journal:  BMC Cancer       Date:  2021-02-03       Impact factor: 4.430

6.  SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.

Authors:  Yushi Nagaki; Satoru Motoyama; Yusuke Sato; Akiyuki Wakita; Hiromu Fujita; Yoshihiro Sasaki; Kazuhiro Imai; Yoshihiro Minamiya
Journal:  World J Surg Oncol       Date:  2021-04-09       Impact factor: 2.754

7.  Impact of the number of resected lymph nodes on survival after preoperative radiotherapy for esophageal cancer.

Authors:  San-Gang Wu; Zhao-Qiang Zhang; Wen-Ming Liu; Zhen-Yu He; Feng-Yan Li; Huan-Xin Lin; Jia-Yuan Sun; Hui Lin; Qun Li
Journal:  Oncotarget       Date:  2016-04-19

8.  Clinical features and treatment of patients with esophageal cancer and a history of gastrectomy: a multicenter, questionnaire survey in Kyushu, Japan.

Authors:  H Okumura; N Mori; T Tanaka; M Morita; Y Toh; H Saeki; Y Maehara; K Nakamura; H Honda; N Yoshida; H Baba; S Natsugoe
Journal:  Dis Esophagus       Date:  2015-11-06       Impact factor: 3.429

9.  Pathological tumor regression grade of metastatic tumors in lymph node predicts prognosis in esophageal cancer patients.

Authors:  Tomohiro Kadota; Ken Hatogai; Tomonori Yano; Takeo Fujita; Takashi Kojima; Hiroyuki Daiko; Satoshi Fujii
Journal:  Cancer Sci       Date:  2018-05-03       Impact factor: 6.716

10.  EIF3H promotes aggressiveness of esophageal squamous cell carcinoma by modulating Snail stability.

Authors:  Xiaobin Guo; Rui Zhu; Aiping Luo; Honghong Zhou; Fang Ding; Hongxin Yang; Zhihua Liu
Journal:  J Exp Clin Cancer Res       Date:  2020-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.